Cross-Border Alliance Management

Acurit provides cross-border alliance management for U.S. biotech companies partnering with China. We specialize in post-deal alliance management, ensuring your China partnerships deliver operational execution, governance discipline, and strategic alignment.

Many U.S. biotech companies enter licensing agreements with Chinese biotech or pharmaceutical partners to accelerate development and access capital. However, post-deal execution often becomes a bottleneck in execution. Differences in communication style, reporting standards, governance expectations, and decision-making processes between the U.S. and China can delay milestones and erode trust.

Acurit bridges these gaps.

Headquartered in Australia, a strategic English-speaking Asia-Pacific hub, we bridge U.S. biotech and Chinese partners in particular. Acurit supports Western biotech companies in managing complex China alliances across clinical development and strategic programs. We provide structured governance oversight, joint steering committee support, milestone tracking, risk identification, stakeholder alignment, and escalation management.

Our model is flexible. We can embed as your alliance lead, representing your company directly in China-facing discussions, or act as an independent advisor managing the partnership on your behalf. In both models, we ensure clarity, accountability, and forward momentum.

Since 2024, Acurit has been supporting a Boston-based biotech company, Keros Therapeutics, in strengthening its China alliance operational efficiency. Even during significant internal restructuring, our work continued, demonstrating the critical importance of experienced cross-border alliance leadership in maintaining stability and alignment.

For U.S. biotech companies seeking experienced, culturally fluent, and execution-focused alliance management with China, Acurit ensures your post-deal partnership delivers on its scientific and commercial promise.